Caribou Biosciences, Inc. (CRBU) stock
CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3074% below fair value
$0.34−0.01 (-3.43%)
Close on Nov 17, 2026Market cap $36.53MP/E –Yield –
Caribou Biosciences cash
Cash and short-term investments held at the end of each period.
Caribou Biosciences's cash was $113.80M at Jun 30, 2026. For fiscal 2025 it was $142.80M, down 42.7% from the year before. The highest annual figure on record is $413.50M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $142.80M | -42.7% |
| FY2024 | Dec 31, 2024 | $249.40M | -33.0% |
| FY2023 | Dec 31, 2023 | $372.40M | +17.5% |
| FY2022 | Dec 31, 2022 | $317.00M | -23.3% |
| FY2021 | Dec 31, 2021 | $413.50M | +2492.0% |
| FY2020 | Dec 31, 2020 | $15.95M | -61.2% |
| FY2019 | Dec 31, 2019 | $41.07M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $113.80M | -38.1% |
| Q1 FY2026 | Mar 31, 2026 | $118.60M | -44.2% |
| Q4 FY2025 | Dec 31, 2025 | $142.80M | -42.7% |
| Q3 FY2025 | Sep 30, 2025 | $159.20M | -43.3% |
| Q2 FY2025 | Jun 30, 2025 | $183.90M | -41.0% |
| Q1 FY2025 | Mar 31, 2025 | $212.50M | -38.6% |
| Q4 FY2024 | Dec 31, 2024 | $249.40M | -33.0% |
| Q3 FY2024 | Sep 30, 2024 | $281.00M | -29.2% |
| Q2 FY2024 | Jun 30, 2024 | $311.80M | +6.6% |
| Q1 FY2024 | Mar 31, 2024 | $345.90M | +18.9% |
| Q4 FY2023 | Dec 31, 2023 | $372.40M | +17.5% |
| Q3 FY2023 | Sep 30, 2023 | $396.70M | +15.8% |
| Q2 FY2023 | Jun 30, 2023 | $292.50M | -20.1% |
| Q1 FY2023 | Mar 31, 2023 | $291.00M | -25.5% |
| Q4 FY2022 | Dec 31, 2022 | $317.00M | -23.3% |
| Q3 FY2022 | Sep 30, 2022 | $342.60M | -21.3% |
| Q2 FY2022 | Jun 30, 2022 | $366.10M | +182.7% |
| Q1 FY2022 | Mar 31, 2022 | $390.80M | +167.8% |
| Q4 FY2021 | Dec 31, 2021 | $413.50M | +2492.0% |
| Q3 FY2021 | Sep 30, 2021 | $435.31M | +1673.4% |
| Q2 FY2021 | Jun 30, 2021 | $129.52M | +291.0% |
| Q1 FY2021 | Mar 31, 2021 | $145.92M | +255.3% |
| Q4 FY2020 | Dec 31, 2020 | $15.95M | – |
| Q3 FY2020 | Sep 30, 2020 | $24.55M | – |
| Q2 FY2020 | Jun 30, 2020 | $33.13M | – |
| Q4 FY2019 | Dec 31, 2019 | $41.07M | – |
See a number that looks wrong?